Journey Medical announces Emrosi featured on “The Balancing Act”

Journey Medical (DERM) announced that a new segment of “The Balancing Act” airing on Lifetime TV and sponsored by the Company featured Emrosi, its FDA-approved treatment for inflammatory lesions of rosacea in adults. The segment premiered nationwide on Monday, June 9, at 7:30 a.m. PT / ET and provided expert insights on lifestyle considerations and treatment options for managing rosacea. The feature included insights from Pura Dermatology’s Saurabh Lodha, MD, FAAD, who discussed Emrosi’s unique formulation and its significance in the treatment landscape for rosacea. Approved by the U.S. Food and Drug Administration in November 2024, Emrosi is the lowest-dose oral minocycline available, offering patients an effective treatment option with a favorable safety profile. It is available by prescription at specialty pharmacy chains.